Deals
Acorda Rises Most Since 2009 on $525 Million Civitas Deal
This article is for subscribers only.
Acorda Therapeutics Inc. gained the most in nearly five years after agreeing to buy Civitas Therapeutics Inc., the developer of an experimental Parkinson’s disease therapy.
Shares of Ardsley, New York-based Acorda rose 28 percent to close at $37.69 in New York, the biggest single-day gain since October 2009, according to data compiled by Bloomberg.